Literature DB >> 14695784

Alteration of somatostatin receptor subtype 2 gene expression in pancreatic tumor angiogenesis.

Ren-Yi Qin1, Ru-Liang Fang, Manoj Kumar Gupta, Zheng-Ren Liu, Da-Yu Wang, Qing Chang, Yi-Bei Chen.   

Abstract

AIM: To explore the difference of somatostatin receptor subtype 2 (SST2R) gene expression in pancreatic cancerous tissue and its adjacent tissue, and the relationship between the change of SST2R gene expression and pancreatic tumor angiogenesis related genes.
METHODS: The expressions of SST2R, DPC4, p53 and ras genes in cancer tissues of 40 patients with primary pancreatic cancer, and the expression of SST2R gene in its adjacent tissue were determined by immunohistochemiscal LSAB method and EnVision(TM) method. Chi-square test was used to analyze the difference in expression of SST2R in pancreatic cancer tissue and its adjacent tissue, and the correlation of SST2R gene expression with the expression of p53, ras and DPC4 genes.
RESULTS: Of the tissue specimens from 40 patients with primary pancreatic cancer, 35 (87.5%) cancer tissues showed a negative expression of SST2R gene, whereas 34 (85%) a positive expression of SST2R gene in its adjacent tissues. Five (12.5%) cancer tissues and its adjacent tissues simultaneously expressed SST2R. The expression of SST2R gene was markedly higher in pancreatic tissues adjacent to cancer than in pancreatic cancer tissues (P<0.05). The expression rates of p53, ras and DPC4 genes were 50%, 60% and 72.5%, respectively. There was a significant negative correlation of SST2R with p53 and ras genes (chi(1)(2)=9.33, chi(2)(2)=15.43, P<0.01), but no significant correlation with DPC4 gene (chi(2)=2.08, P>0.05).
CONCLUSION: There was a significant difference of SST2R gene expression in pancreatic cancer tissues and its adjacent tissues, which might be one cause for the different therapeutic effects of somatostatin and its analogs on pancreatic cancer patients. There were abnormal expressions of SST2R, DPC4, p53 and ras genes in pancreatic carcinogenesis, and moreover, the loss or decrease of SST2R gene expression was significantly negatively correlated with the overexpression of tumor angiogenesis correlated p53 and ras genes, suggesting that SST2R gene together with p53 and ras genes may participate in pancreatic cancerous angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14695784      PMCID: PMC4717065          DOI: 10.3748/wjg.v10.i1.132

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

Review 1.  Octreotide in the management of hormone-refractory prostate cancer.

Authors:  I G Vainas
Journal:  Chemotherapy       Date:  2001       Impact factor: 2.544

2.  Treatment of hepatocellular carcinoma with long acting somatostatin analogues.

Authors:  Demetrios N Samonakis; Joanna Moschandreas; Theodora Arnaoutis; Panagiotis Skordilis; Christos Leontidis; Irene Vafiades; Elias Kouroumalis
Journal:  Oncol Rep       Date:  2002 Jul-Aug       Impact factor: 3.906

Review 3.  Chemoprevention for pancreatic cancer.

Authors:  Robert A Wolff
Journal:  Int J Gastrointest Cancer       Date:  2003

4.  Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.

Authors:  E Kouroumalis; P Skordilis; K Thermos; A Vasilaki; J Moschandrea; O N Manousos
Journal:  Gut       Date:  1998-03       Impact factor: 23.059

5.  Expression of somatostatin receptor subtypes and growth inhibition in human exocrine pancreatic cancers.

Authors:  T Kikutsuji; M Harada; S Tashiro; S Ii; M Moritani; T Yamaoka; M Itakura
Journal:  J Hepatobiliary Pancreat Surg       Date:  2000

6.  Inhibitory role of the somatostatin receptor SST2 on the intracrine-regulated cell proliferation induced by the 210-amino acid fibroblast growth factor-2 isoform: implication of JAK2.

Authors:  Marylis Hortala; Geraldine Ferjoux; Agnes Estival; Claudine Bertrand; Stefan Schulz; Lucien Pradayrol; Christiane Susini; Francois Clemente
Journal:  J Biol Chem       Date:  2003-03-27       Impact factor: 5.157

Review 7.  [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].

Authors:  Eva Hofsli
Journal:  Tidsskr Nor Laegeforen       Date:  2002-02-20

8.  Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.

Authors:  Siegbert Faiss; Ulrich-Frank Pape; Michael Böhmig; Yvonne Dörffel; Ulrich Mansmann; Werner Golder; Ernst Otto Riecken; Bertram Wiedenmann
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

9.  Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis.

Authors:  Julie Guillermet; Nathalie Saint-Laurent; Philippe Rochaix; Olivier Cuvillier; Thierry Levade; Andrew V Schally; Lucien Pradayrol; Louis Buscail; Christiane Susini; Corinne Bousquet
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-18       Impact factor: 11.205

10.  Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme.

Authors:  Michael Bacher; Jörg Schrader; Nancy Thompson; Karen Kuschela; Diethard Gemsa; Gérard Waeber; Jürgen Schlegel
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

View more
  3 in total

1.  Gene transfer of somatostatin receptor type 2 by intratumoral injection inhibits established pancreatic carcinoma xenografts.

Authors:  Zhi-Yong Du; Ren-Yi Qin; Wei Xia; Rui Tian; Manoj Kumar
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

2.  Effects of recombinant human canstatin protein in the treatment of pancreatic cancer.

Authors:  Xiao-Ping He; Zhao-Shen Li; Ren-Min Zhu; Zhen-Xing Tu; Jun Gao; Xue Pan; Yan-Fang Gong; Jing Jin; Xiao-Hua Man; Hong-Yu Wu; Ai-Fang Xu
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

3.  Impact of Octreotide and SOM-230 on liver metastasis and hepatic lipidperoxidation in ductal pancreatic adenocarcinoma in Syrian Hamster.

Authors:  M Kilian; J I Gregor; I Heukamp; K Helmecke; M Hanel; B Wassersleben; M K Walz; I Schimke; G Kristiansen; F A Wenger
Journal:  Clin Exp Metastasis       Date:  2009-06-12       Impact factor: 5.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.